Femasys Announces Infertility Clinic Customers from Coast to Coast ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility -- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI)...

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 -- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution -- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme...

A Managed Fertility Benefit Offers Significant Costs Savings for Employers and Drives More Successful Family-building Outcomes for Employees, Experts Say New York, N.Y., Feb. 21, 2020 (GLOBE NEWSWIRE) -- The American family is evolving, signaling cultural and economic shifts that are here to stay. American’s are delaying marriage, waiting longer to...